Contribution of cytochrome P450 and UDT-glucuronosyltransferase to the metabolism of drugs containing carboxylic acid groups: risk assessment of acylglucuronides using human hepatocytes

References

• Baillie TA. (2006). Future of toxicology-metabolic activation and drug design: challenges and opportunities in chemical toxicology. Chem Res Toxicol 19:889–93
   PubMed Web of Science ®Google Scholar
• Bauman JN, Kelly JM, Tripathy S, et al. (2009). Can in vitro metabolism-dependent covalent binding data distinguish hepatotoxic from nonhepatotoxic drugs? An analysis using human hepatocytes and liver S-9 fraction. Chem Res Toxicol 22:332–40
   PubMed Web of Science ®Google Scholar
• Benet LZ, Spahn-Langguth H, Iwakawa S, et al. (1993). Predictability of the covalent binding of acidic drugs in man. Life Sci 53:PL141–6
   PubMed Web of Science ®Google Scholar
• Bolze S, Lacombe O, Durand G, et al. (2002). Standardization of a LC/MS/MS method for the determination of acyl glucuronides and their isomers. Curr Sep 20:55–9
   Google Scholar
• Davies B, Morris T. (1993). Physiological parameters in laboratory animals and humans. Pharm Res (NY) 10:1093–5
   PubMed Web of Science ®Google Scholar
• Di L, Umland JP, Chang G, et al. (2011). Species independence in brain tissue binding using brain homogenates. Drug Metab Dispos 39:1270–7
   PubMed Web of Science ®Google Scholar
• Di L, Keefer C, Scott DO, et al. (2012). Mechanistic insights from comparing intrinsic clearance values between human liver microsomes and hepatocytes to guide drug design. Eur J Med Chem 57:441–8
   PubMed Web of Science ®Google Scholar
• Ebner T, Heinzel G, Prox A, et al. (1999). Disposition and chemical stability of telmisartan 1-O-acylglucuronide. Drug Metab Dispos 27:1143–9
   PubMed Web of Science ®Google Scholar
• Emoto C, Murase S, Sawada Y, et al. (2003). In vitro inhibitory effect of 1-aminobenzotriazole on drug oxidations catalyzed by human cytochrome P450 enzymes: a comparison with SKF-525A and ketoconazole. Drug Metab Pharmacokinet 18:287–95
   PubMedGoogle Scholar
• Evans DC, Watt AP, Nicoll-Griffith DA, Baillie TA. (2004). Drug-protein adducts: an industry perspective on minimizing the potential for drug bioactivation in drug discovery and development. Chem Res Toxicol 17:3–16
   PubMed Web of Science ®Google Scholar
• Ishii Y, Iida N, Miyauchi Y, et al. (2012). Inhibition of morphine glucuronidation in the liver microsomes of rats and humans by monoterpenoid alcohols. Biol Pharm Bull 35:1811–17
   PubMed Web of Science ®Google Scholar
• Iwatsubo T, Hirota N, Ooie T, et al. (1997). Prediction of in vivo drug metabolism in the human liver from in vitro metabolism data. Pharmacol Ther 73:147–71
   PubMed Web of Science ®Google Scholar
• Jean P, Lopez-Garcia P, Dansette P, et al. (1996). Oxidation of tienilic acid by human yeast-expressed cytochromes P-450 2C8, 2C9, 2C18 and 2C19. Evidence that this drug is a mechanism-based inhibitor specific for cytochrome P-450 2C9. Eur J Biochem 241:797–804
   PubMedGoogle Scholar
• Jinno N, Ohashi S, Tagashira M, et al. (2013). A simple method to evaluate reactivity of acylglucuronides optimized for early stage drug discovery. Biol Pharm Bull 36:1509–13
   PubMed Web of Science ®Google Scholar
• Jones RD, Jones HM, Rowland M, et al. (2011). PhRMA CPCDC initiative on predictive models of human pharmacokinetics, part 2: comparative assessment of prediction methods of human volume of distribution. J Pharm Sci 100:4074–89
   PubMed Web of Science ®Google Scholar
• Kaplowitz N. (2005). Idiosyncratic drug hepatotoxicity. Nat Rev Drug Discov 4:489–99
   PubMed Web of Science ®Google Scholar
• Kimoto E, Walsky R, Zhang H, et al. (2012). Differential modulation of cytochrome P450 activity and the effect of 1-aminobenzotriazole on hepatic transport in sandwich-cultured human hepatocytes. Drug Metab Dispos 40:407–11
   PubMed Web of Science ®Google Scholar
• Koga T, Fujiwara R, Nakajima M, Yokoi T. (2011). Toxicological evaluation of acyl glucuronides of nonsteroidal anti-inflammatory drugs using human embryonic kidney 293 cells stably expressing human UDP-glucuronosyltransferase and human hepatocytes. Drug Metab Dispos 39:54–60
   PubMed Web of Science ®Google Scholar
• Li AP. (2002). A review of the common properties of drugs with idiosyncratic hepatotoxicity and the ‘‘multiple determinant hypothesis’’ for the manifestation of idiosyncratic drug toxicity. Chem Biol Interact 142:7–23
   PubMed Web of Science ®Google Scholar
• Lombardo F, Waters NJ, Argikar UA, et al. (2013a). Comprehensive assessment of human pharmacokinetic prediction based on in vivo animal pharmacokinetic data, part 1: volume of distribution at steady state. J Clin Pharmacol 53:167–77
   PubMed Web of Science ®Google Scholar
• Lombardo F, Waters NJ, Argikar UA, et al. (2013b). Comprehensive assessment of human pharmacokinetic prediction based on in vivo animal pharmacokinetic data, part 2: clearance. J Clin Pharmacol 53:178–91
   PubMed Web of Science ®Google Scholar
• Mano Y, Usui T, Kamimura H. (2007). The UDP-glucuronosyltransferase 2B7 isozyme is responsible for gemfibrozil glucuronidation in the human liver. Drug Metab Dispos 35:2040–4
   PubMed Web of Science ®Google Scholar
• Masubuchi N, Makino C, Murayama N. (2007). Prediction of in vivo potential for metabolic activation of drugs into chemically reactive intermediate: correlation of in vitro and in vivo generation of reactive intermediates and in vitro glutathione conjugate formation in rats and humans. Chem Res Toxicol 20:455–64
   PubMed Web of Science ®Google Scholar
• Naisbitt DJ, Sanderson LS, Meng X, et al. (2007). Investigation of the immunogenicity of diclofenac and diclofenac metabolites. Toxicol Lett 168:45–50
   PubMed Web of Science ®Google Scholar
• Nakayama S, Atsumi R, Takakusa H, et al. (2009). A zone classification system for risk assessment of idiosyncratic drug toxicity using daily dose and covalent binding. Drug Metab Dispos 37:1970–7
   PubMed Web of Science ®Google Scholar
• Nakayama S, Takakusa H, Watanabe A, et al. (2011). Combination of GSH trapping and time-dependent inhibition assays as a predictive method of drugs generating highly reactive metabolites. Drug Metab Dispos 39:1247–54
   PubMed Web of Science ®Google Scholar
• Obach RS, Kalgutkar AS, Soglia JR, Zhao SX. (2008). Can in vitro metabolism-dependent covalent binding data in liver microsomes distinguish hepatotoxic from nonhepatotoxic drugs? An analysis of 18 drugs with consideration of intrinsic clearance and daily dose. Chem Res Toxicol 21:1814–22
   PubMed Web of Science ®Google Scholar
• Reese M, Sakatis M, Ambroso J, et al. (2010). An integrated reactive metabolite evaluation approach to assess and reduce safety risk during drug discovery and development. Chem Biol Interact 192:60–4
   PubMed Web of Science ®Google Scholar
• Ring BJ, Chien JY, Adkison KK, et al. (2011). PhRMA CPCDC initiative on predictive models of human pharmacokinetics, part 3: comparative assessment of prediction methods of human clearance. J Pharm Sci 100:4090–110
   PubMed Web of Science ®Google Scholar
• Roberts MS, Rowland M. (1986). Correlation between in-vitro microsomal enzyme activity and whole organ hepatic elimination kinetics: analysis with a dispersion model. J Pharm Pharmacol 38:177–81
   PubMed Web of Science ®Google Scholar
• Sakaguchi K, Green M, Stock N, et al. (2004). Glucuronidation of carboxylic acid containing compounds by UDP-glucuronosyltransferase isoforms. Arch Biochem Biophys 424:219–25
   PubMed Web of Science ®Google Scholar
• Sawamura R, Okudaira N, Watanabe K, et al. (2010). Predictability of idiosyncratic drug toxicity risk for carboxylic acid-containing drugs based on the chemical stability of acyl glucuronide. Drug Metab Dispos 38:1857–64
   PubMed Web of Science ®Google Scholar
• Shibata Y, Takahashi H, Chiba M, Ishii Y. (2002). Prediction of hepatic clearance and availability by cryopreserved human hepatocytes: an application of serum incubation method. Drug Metab Dispos 30:892–6
   PubMed Web of Science ®Google Scholar
• Spahn-Langguth H, Benet LZ. (1992). Acyl glucuronides revisited: is the glucuronidation process a toxification as well as a detoxification mechanism? Drug Metab Rev 24:5–47
   PubMed Web of Science ®Google Scholar
• Sohlenius-Sternbeck AK, Afzelius L, Prusis P, et al. (2010). Evaluation of the human prediction of clearance from hepatocyte and microsome intrinsic clearance for 52 drug compounds. Xenobiotica 40:637–49
   PubMed Web of Science ®Google Scholar
• Sohlenius-Sternbeck AK, Jones C, Ferguson D, et al. (2012). Practical use of the regression offset approach for the prediction of in vivo intrinsic clearance from hepatocytes. Xenobiotica 42:841–53
   PubMed Web of Science ®Google Scholar
• Thompson RA, Isin EM, Li Y, et al. (2010). Risk assessment and mitigation strategies for reactive metabolites in drug discovery and development. Chem Biol Interact 192:65–71
   PubMed Web of Science ®Google Scholar
• Thompson RA, Isin EM, Li Y et al. (2012). In vitro approach to assess the potential for risk of idiosyncratic adverse reactions caused by candidate drugs. Chem Res Toxicol 25:161632
   Google Scholar
• Uetrecht J. (2001). Prediction of a new drug’s potential to cause idiosyncratic reactions. Curr Opin Drug Discov Dev 4:55–9
   PubMedGoogle Scholar
• Uetrecht J. (2007). Idiosyncratic drug reactions: current understanding. Annu Rev Pharmacol Toxicol 47:513–39
   PubMed Web of Science ®Google Scholar
• Usui T, Mise M, Hashizume T, et al. (2009). Evaluation of the potential for drug-induced liver injury based on in vitro covalent binding to human liver proteins. Drug Metab Dispos 37:2383–92
   PubMed Web of Science ®Google Scholar
• Vuppugalla R, Marathe P, He H, et al. (2011). PhRMA CPCDC initiative on predictive models of human pharmacokinetics, part 4: prediction of plasma concentration-time profiles in human from in vivo preclinical data by using the Wajima approach. J Pharm Sci 100:4111–26
   PubMed Web of Science ®Google Scholar